middle.news
Argenica’s Phase 2 Stroke Trial Clears Safety Hurdle, Nears Completion
9:17am on Thursday 30th of January, 2025 AEDT
•
Biotechnology
Read Story
Argenica’s Phase 2 Stroke Trial Clears Safety Hurdle, Nears Completion
9:17am on Thursday 30th of January, 2025 AEDT
Key Points
DSMB recommends continuation of Phase 2 trial with no protocol changes
79 of 92 patients dosed, representing 86% trial completion
One serious adverse event possibly related to study drug but trial deemed safe
Final DSMB review completed, no further safety reviews planned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE